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Abstract
Muscle differentiation is a highly conserved process that occurs through the activation of quiescent satellite cells whose
progeny proliferate, differentiate, and fuse to generate new myofibers. A defined pattern of myogenic transcription factors
is orchestrated during this process and is regulated via distinct signaling cascades involving various intracellular signaling
pathways, including members of the protein kinase C (PKC) family. The protein kinase D (PKD) isoenzymes PKD1, -2, and -3,
are prominent downstream targets of PKCs and phospholipase D in various biological systems including mouse and could
hence play a role in muscle differentiation. In the present study, we used a mouse myoblast cell line (C2C12) as an in vitro
model to investigate the role of PKDs, in particular PKD2, in muscle stem cell differentiation. We show that C2C12 cells
express all PKD isoforms with PKD2 being highly expressed. Furthermore, we demonstrate that PKD2 is specifically
phosphorylated/activated during the initiation of mouse myoblast differentiation. Selective inhibition of PKCs or PKDs by
pharmacological inhibitors blocked myotube formation. Depletion of PKD2 by shRNAs resulted in a marked inhibition of
myoblast cell fusion. PKD2-depleted cells exhibit impaired regulation of muscle development-associated genes while the
proliferative capacity remains unaltered. Vice versa forced expression of PKD2 increases myoblast differentiation. These
findings were confirmed in primary mouse satellite cells where myotube fusion was also decreased upon inhibition of PKDs.
Active PKD2 induced transcriptional activation of myocyte enhancer factor 2D and repression of Pax3 transcriptional
activity. In conclusion, we identify PKDs, in particular PKD2, as a major mediator of muscle cell differentiation in vitro and
thereby as a potential novel target for the modulation of muscle regeneration.
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Introduction
The process of skeletal muscle differentiation is characterized by
mononucleated myoblasts exiting cell cycle and fusing to form
multinucleated myotubes. This process is orchestrated at the
molecular level by the expression of the myogenic basic helix-loop-
helix (bHLH) transcription factors MyoD, Myf5, myogenin, and
MRF4[1]. Myogenic bHLH factors cooperate with each other and
with the myocyte enhancer factor-2 (MEF-2) family of transcrip-
tion factors to regulate their own expression in a feedback loop
that maintains the transcriptional program [2,3,4,5]. This results
in expression of myofibrillar proteins, such as myosin heavy chain
(MHC)[6]. In addition to myogenic transcription factors, several
protein kinases including p38-MAPK [7], PLD [8] and PKC
isoforms [9,10] have been implicated in the regulation of skeletal
muscle stem cell differentiation.
The protein kinase D (PKD) family belongs to the calcium-/
calmodulin-dependent protein kinase superfamily [11] and com-
prises the three isoforms, PKD1, -2 and -3 [12]. PKDs are activated
by various stimuli, including phorbol esters, G-protein-coupled
receptors and reactive oxygen species [12,13]. PKDs are serine
threonine kinases and act as prominent downstream targets of
PKCs, including novel PKCg and e [14,15]. PKCs directly activate
PKDs via phosphorylation at two critical serine residues within the
activation loop of the catalytic domain [16]. However, PKDs can
also be activated by direct binding of diacylglycerol (DAG) to the
C1a domain within their regulatory domain [17]. The members of
this family play a role in cell motility, migration, and invasion.
Furthermore, they regulate protein transport by inducing the fission
of budding vesicles from the trans-Golgi network [18,19,20,21].
Interestingly, members of the PKD family were found to play a role
in skeletal, cardiac, and smooth muscle regulative processes: PKD1
stimulates MEF2 activity in skeletal muscle, enhances muscle
performance and plays a crucial role in pathological heart
remodeling [22,23]. In addition, the hypertrophic response to
angiotensin II in smooth muscle cells is mediated by PKDs [24].
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dependent on a small population of resident cells termed satellite
cells which are capable of terminal differentiation during these
processes. Here, we examined a potential role of PKDs during
myogenic differentiation using murine C2C12 myoblasts to
recapitulate myogenic differentiation. These cells differentiate
rapidly, form contractile myotubes, express characteristic marker
genes and, therefore, serve as a bona fide in vitro model to study the
differentiation of myoblasts to myotubes [25].
We show that C2C12 cells predominantly express PKD2 and
PKD3. PKD2 was found to be the major PKD isoform that was
catalytically active during the early phase of differentiation of
C2C12 cells to skeletal muscle cells. Pharmacological inhibition of
PKCs or PKDs led to a markedly decreased differentiation of
C2C12 cells. Ectopic expression of active PKD2 induced
transcriptional activation of Mef2D and inhibited transcriptional
activity of Pax3 in these cells. Furthermore, selective depletion of
PKD2 by specific shRNAs was sufficient to inhibit/prevent
differentiation of C2C12 cells. Vice versa overexpressed PKD2
induced differentiation. Collectively, our data demonstrate an
essential role of PKD2 in the differentiation of precursor cells to
skeletal muscle cells potentially leading to novel treatment
strategies for in vivo muscle regeneration.
Results
Expression of PKDs in C2C12 cells and adult skeletal
muscle
PKDs are expressed in the developing mouse embryo. In
particular PKD2 shows a differential regulated expression pattern
and is highly abundant in the heart and striated muscles while
PKD3 lacks striated muscle expression [26]. Additionally PKDs
play a major role in terminally differentiated muscle types.
Therefore, we investigated the expression of PKD isoforms in the
mouse myoblast cell line C2C12 in order to assess whether PKDs
could be important for myogenic stem cell differentiation. As
shown in Figure 1A, PKD2 and PKD3 were highly expressed in
C2C12 cells and appeared as the predominant PKD isoforms of
this particular cell type. PKD1 was found to be expressed at very
low levels compared to the other isoforms in C2C12 cells at both,
the protein and the mRNA level (Figure 1A and 1C). In
terminally differentiated murine skeletal muscles, PKD2 was found
to be the predominant isoform (Figure 1B).
Next, we examined the expression of the various PKD isoforms
during myoblast differentiation in the C2C12 cell system. As
shown in Figure 1C, there was very little PKD1 expression at
baseline. In addition, PKD1-mRNA did not change substantially
during differentiation (Figure 1C). In contrast, there was an
immediate, 6-fold increase in PKD2 mRNA at day 1 after
initiation of differentiation whereas PKD2 mRNA levels were
markedly lower during the terminal myotube stages (Figure 1D).
Interestingly, PKD3 mRNA expression exhibited different kinetics
during differentiation of C2C12 cells: PKD3 mRNA was only
slightly induced upon initiation of differentiation and during mid
stage differentiation, but peaked at day 6 of myotube differenti-
ation (Figure 1E). These data suggest that PKD2 could be the
major isoform involved in the early stages of myogenic
differentiation.
PKD2 is activated by sphingosine-1-phosphate (S1P) in
C2C12 cells
Next, we were interested whether agents known to induce
myogenic differentiation were able to activate PKDs. Insulin like
growth factors (IGFs) are major mediators of myogenic stem cell
differentiation [27,28,29] and have been described to activate
PKDs [30]. However, in contrast to myeloma cells, incubation of
undifferentiated C2C12 cells with different concentrations of IGF-
1 did not result in activation of PKD2 (data not shown). Another
ligand known to be involved in myogenic differentiation is the
bioactive lipid S1P that acts on a heptahelical receptors [31]. S1P
acts as a powerful pro-differentiating agent by enhancing the
expression of myogenic differentiation markers such as myogenin,
myosin heavy chain, and caveolin-3 [31,32,33]. As shown in
Figure 2A and 2B, S1P markedly stimulated PKD phosphor-
ylation/activation. Thus, PKDs can be activated by a known
stimulator (S1P) of myogenic differentiation in C2C12 cells.
PKD2 is activated during the initiation of myoblast
differentiation
Since PKD2 was found be the major isoform expressed during
the initial stages of differentiation at the level of gene expression,
we focussed on the role of this isoform in the process of muscle
stem cell differentiation. To examine the role of PKD2 in
myogenesis, we assessed PKD2 expression and activity in C2C12
cells upon differentiation. C2C12 cells grown to 90% confluence
were induced to differentiate by serum withdrawal. Typically, cell
fusion and formation of small myotubes were evident 3 days after
induction and myotubes were fully formed within 5-6 days
(Figure S1). PKD2 protein expression correlated with mRNA
expression profiles and slowly decreased during differentiation
(Figure 3A). The PKD2 antibody used in this study was specific in
detecting only PKD2 and did not show cross reactivity with either
PKD1 or PKD3 (Figure S2). Undifferentiated C2C12 cells grown
to confluency also exhibited a substantial basal PKD activity as
demonstrated by PKD phosphorylation within the activation loop
at two conserved serine residues that indicate catalytic activity
(Figure 3A) [15]. Activation loop phosphorylation and therefore
PKD catalytic activity were significantly further increased upon
initiation of differentiation by serum withdrawal (two-fold increase,
Figure 3B). Our hypothesis that PKD2 is the major isoform that
is activated in the muscle stem cell differentiation process was
further substantiated by immunoprecipitation of PKD2 followed
by detection of PKD2 activation using the phospho-specific PKD
antibody (Figure 3C). PKD2 activity was increased on day 1 of
differentiation.
PKD2 activation and peak protein expression were followed by
increased myogenin and MyoD expression; both are key players in
the initiation process of myogenesis. As a control for the
differentiation process in our cell culture system, we determined
the expression of MHC that gradually increased as expected until
day 5 (Figure 3A). Hence, PKD phosphorylation coincides with
both critical initiation steps of myoblast differentiation, namely cell
density and serum starvation. (Figure 3A–C).
Activation loop phosphorylation and hence catalytic activity of
PKD could be further increased upon incubation of subconfluent,
undifferentiated C2C12 cells with the phorbol ester PMA, a potent
activator of both PKCs and PKDs (Figure 3D) [12]. PKCs are
major regulators of PKD activity in various cell systems [15].
Go ¨6983 inhibits predominantly the catalytic activity of classical
and novel PKCs g,h,d,e whereas Go ¨6976 selectively inhibits the
classical PKCa and PKDs [34]. Incubation of cells with Go ¨6983
(5 mM) completely abrogated basal and PMA-stimulated activa-
tion of PKD demonstrating that PKCs are major regulators of
PKDs also in C2C12 cells (Figure 3D). The selective PKD
inhibitor Go ¨6976 (5 mM) also inhibited PKD phosphorylation in
subconfluent C2C12 cells. The effect of both inhibitors on PMA-
induced PKD2 phosphorylation was concentration-dependent
with a maximum inhibitory effect observed between 5 and
PKD2 Regulates Differentiation
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could also abolish differentiation-induced PKD phosphorylation,
we treated confluent C2C12 cells with the respective inhibitors
after serum withdrawal. PKD phosphorylation in response to
serum withdrawal was blocked by both inhibitors during
differentiation (Figure 3E and 3F). Thus, PKDs are constitu-
tively phosphorylated within the activation loop in subconfluent,
undifferentiated C2C12 cells and activation of PKDs is mediated
by PKCs in these cells. Activation of PKDs in response to
differentiation-inducing agents can be blocked by Go ¨6983 and
Go ¨6976.
Pharmacological inhibition of PKCs and PKDs inhibits
myoblast differentiation in vitro
Next, we were interested whether PKD2 activity is required for
myogenesis. C2C12 cells were differentiated for 5 days by serum
withdrawal in the presence of Go ¨6983 or Go ¨6976 to inhibit PKC/
PKD activity. As shown in Figure 4A, treatment with Go ¨6983 or
Go ¨6976 reduced the degree of C2C12 differentiation as evidenced
by visualizing MHC-positive myotubes. DAPI staining was
performed to determine cell density and calculation of the fusion
index (channel not shown). F-actin staining was used to visualize the
morphology of all cell types. The solvent control did not exhibit any
effect on differentiation. Inhibitor treatment markedly reduced the
total number of myotubes per visual field at day 3 (Figure 4A and
4B) and day 5 (Figure S3A and S3B). This suggests an effect of the
inhibitors already during the initiation of differentiation as MHC
exclusively stains differentiated myoblasts already expressing
myofibrillar proteins. To assess the differential effects of the
inhibitors more precisely, we calculated not only the number of
myotubes per visual field but also the fusion index to assess the
relative differentiation potential. Separate treatment of cells with
both inhibitors dramatically reduced the fusion index in all groups
(Figure 4C and Figure S3C). At 10 mMG o ¨6976 induced cell
death. Go ¨6983 used at the same concentration induced less cell
death (data not shown), but was also less potent in reducing the
fusion index compared to Go ¨6976 (Figure 4B and 4C). Notably,
the morphology of myotubes differed in both inhibitor-treated
groups. Go ¨6983-treated myotubes displayed a significantly de-
creased length-to-width ratio whileinGo ¨6976-treatedmyotubes the
length-to-width ratio was increased compared to control cells both
at day 3 and day 5 (Figure S4). Given that Go ¨6983 predominantly
inhibits PKCs and Go ¨6976 PKDs, these data suggest that PKDs
may have additional roles in myoblast differentiation apart from
acting as PKC downstream targets. Both, Go ¨6976 and Go ¨6983
significantly reduced the expression of the contractile protein MHC
in C2C12 cells (Figure 4D).
shRNA-mediated PKD2 depletion inhibits myoblast
differentiation in vitro
To specifically address the role of PKD2 during myoblast
differentiation, we depleted PKD2 in C2C12 cells by lentiviral
mediated shRNAs targeting specifically PKD2. Initially, stable cell
lines with four independent shRNAs targeting the PKD2 gene were
generated.A celllinecarrying the pLKOvectorwithGFPserved asa
negative control (Control, Con). shRNAs targeting PKD2 specifically
reduced the amount of PKD2 protein by either 50% (#PKD2-2) or
90% (#PKD2-4). PKD1 and -3 protein levels were not altered by the
PKD2 shRNA (data not shown). The shRNA constructs #PKD2-1
and 3 did not have a significant effect on PKD2 expression
Figure 1. PKD2 is the predominant isoform in undifferentiated and in differentiated C2C12 cells. (A) Immunoblot analysis for PKD1, 2,
and 3 in undifferentiated C2C12 cells. Murine embryonic fibroblasts and NIH3T3 fibroblasts served as controls. One representative blot from three
independent experiments is shown. (B) Immunoblot analysis for PKD1, 2, and 3 in terminally differentiated murine skeletal muscle. Lysates of the
right and left tibial anterior muscle of two mice are shown. (C–E) qPCR analysis of PKD1 (C), PKD2 (D), and PKD3 (E) expression over time in C2C12
cells and their differentiated progeny at the indicated time points. Relative gene expression was determined as a ratio of target gene concentration to
the concentration of a housekeeping gene, murine hydroxymethylbilane synthase (mHMBS). Three independent experiments 6SEM were tested for
significance using the Student’s t-test. P,0.05 (*) and p,0.01 (
**) are indicated.
doi:10.1371/journal.pone.0014599.g001
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morphology and a reduced number of myotubes (Figure 5B). Gene
expression analysis during differentiation revealed strongly altered
expression profiles in both PKD2 depleted cell lines (#PKD2-2,
#PKD2-4; Figure S5A-E). The activation of satellite cells is
associatedwithaninitialsimultaneousstimulationofPax7andMyoD
expression. The downregulation of Pax7 by constant MyoD
expression is described to be the initial signal for differentiation of
the cells (Figure S5A–B) [35,36,37,38]. When Pax 7 is down-
regulated, myogenin expression starts in line with a previous data
showing that their expression is mutually exclusive (Figure S5C)
[38]. Control cultures also showed a first expression peak of MEF2D
after 72 hours of differentiation as previously described and the
expected continuous up-regulation of the more mature differentiation
marker nicotinic, cholinergic receptor (Figure S5D and S5E)[ 3 9 ] .
Scrambled shRNA knock down cultures exhibited the expected
expression pattern of muscle markers. In striking contrast, the PKD2-
depleted cultures showed substantially reduced expression of all
markers mentioned. However, the sequence of the marker expression
course was regular (Figure S5A–E). Immunoblot analysis also
revealed a significantly reduced MHC expression (Figure 5C and
5D). MHC was also analyzed by immunocytochemistry. The
number of myotubes per visual field was quantified and the fusion
indices were calculated (Figure 5E). The total number of myotubes
per visual field was significantly reduced in PKD2-depleted C2C12
cells (Figure 5F). PKD2-4 shRNA-expressing cells showed more
single nucleated myocytes indicating that crucial steps required for
adequate cell fusion were impaired. In addition, PKD2-depleted
cultures exhibited a significantly reduced number of multinucleated
myotubes which points to an even more drastic effect during further
myotube formation (Figure 5G). Thus, PKD2 appears to be
required for in vitro myoblast differentiation. The residual, but
substantially reduced differentiation in the PKD2-4 shRNA-express-
ing cells could be explained either an induction of other myogenesis-
inducing pathways, the presence of residual PKD2 protein or an
activation of compensatory mechanisms induced by other PKD
isoforms.
PKD2-depleted cells show normal proliferative capacity
Pharmacological inhibition of PKCs and PKDs using chemical
inhibitors revealed to some extent cell death in the differentiating
cultures. To dissect whether this is due to reduced PKD activity or
Figure 2. PKD2 is activated by sphingosine-1-phosphate (S1P) in C2C12 cells. Subconfluent C2C12 cells were stimulated as indicated in the
figure with (S1P) and further processed for immunoblot analysis for PKD2 and phospho-PKD (Ser 744/748). (A) One representative western blot for
PKD2 and phospho-PKD (Ser 744/748) out of three independent experiments is shown. b-actin served as loading control. (B) Quantification of band
intensity in the shown immunoblot of phospho-PKD expression relative to PKD2 in S1P-stimulated C2C12 cells. Values include 10 min values of
10 mM S1P treatment from all three experiments.
doi:10.1371/journal.pone.0014599.g002
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PLoS ONE | www.plosone.org 4 January 2011 | Volume 6 | Issue 1 | e14599Figure 3. PKD2 is activated during muscle stem cell differentiation. (A) Immunoblot analysis for PKD2 and phospho-PKD (Ser 744/748)
during in vitro differentiation of C2C12 cells at the indicated time points. C2C12 cells express the expected marker profile after induction of
differentiation. Time points are as indicated in the figure. Upper immunoblot shows myogenin followed by MyoD and MHC, respectively. b-actin
served as the corresponding loading control. One representative experiment out of three is shown. (B) Quantification of band intensity of phospho-
PKD expression normalized to PKD2 levels during C2C12 cell differentiation is shown at day 0, 1, and 2. (C) Immunoprecipitation analysis for PKD2
followed by immunoblot for phospho-PKD (Ser 744/748) during in vitro differentiation of C2C12 cells at the indicated time points. One representative
experiment out of three is shown. (D) Undifferentiated, not confluent C2C12 cells were treated for one hour with either 5 mMG o ¨6976 or Go ¨6983:
DMSO served as a solvent control. As indicated, cells were additionally treated with PMA for 10 minutes. After compound treatment, cells were
harvested and subsequently analyzed by immunoblotting using PKD2 or phospho-PKD (Ser 744/748) antibodies. Exposure time was very short in
purpose to avoid overexposure and interference with neighboured bands. Shown is one representative experiment out of two independent
experiments with similar results. (E) C2C12 cells were treated one day prior to induction of differentiation by serum withdrawal with 5 mMG o ¨6976
and 5 mMG o ¨6983. On day 0, cells were switched to low serum conditions. DMSO served as a solvent control. On day 1, cells were lysed and
subsequently analyzed by immunoblotting using PKD2 or phospho-PKD (Ser 744/748) antibodies. Shown is one representative experiment out of
three independent experiments. (F) Quantification of band intensity of phospho-PKD expression normalized to PKD2 levels is shown during C2C12
cell differentiation at day 1.
doi:10.1371/journal.pone.0014599.g003
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effect of PKD2 depletion on cell cycle progression. A cell viability
assay showed no difference in the PKD2-depleted cells compared
to control cultures (Figure S6A). Cell cycle analysis showed also
similar profiles in all three lines (Figure S6B–D) albeit there was a
slight but not significant trend of fewer cells being in S-phase in the
#PKD2-4 cell line (Figure S6B and S6D). Previously it has been
shown that PKDs affect proliferation via interfering with cyclin D
levels [40]. However, we could no detect differences in cyclin D1
levels in all our experiments between control and PKD2-depleted
cells (Figure S6E).
PKD1 and PKD3 are less critical for C2C12 myoblast
differentiation than PKD2
To exclude potential bias from other PKD isoforms, we
generated lentiviral knock down C2C12 cell lines (Figure S7A–
B). PKD1- and PKD3 depleted cell lines were differentiated as in
the previous experiments for PKD2. We chose MyoD as a marker
for the initiation of myogensis and mAch as a late marker to assess
the mature phases of C2C12 myoblast differentiation. We could
not detect a significant difference of MyoD expression in PKD1–
and PKD3-depleted cells compared to scrambled infected C2C12
cells on day 3 and 5 (Figure S7C) pointing to less important role
of these kinases during early muscle differentiation. mAch
expression was similar on day 3 while on day 5 PKD3-depleted
cells showed significantly less mAch. Given the expression profiles
for PKD1, PKD2 and PKD3 (Figure 1C–E) these data are
perfectly in line with our findings pointing to a less important role
of PKD1 throughout C2C12 cell differentiation while PKD3
becomes more critical towards the end of differentiation. However,
further experiments have to clarify these issues in more detail.
Ectopic expression of PKD2 increases myogenic
differentiation
To examine whether PKD2 alone could trigger myogenic
differentiation of C2C12 cells, we inserted wild type PKD2 into a
Figure 4. Pharmacological inhibition of PKCs and PKDs inhibits myoblast differentiation in vitro. (A) Cells were seeded on cover slips
and treated with either Go ¨6976 or Go ¨6983. Concentrations are indicated in the figure. DMSO served as a solvent control. On day 3, cover slips were
stained for MHC (green), F-actin (red) and nuclei (blue). Photographs are representative for 3 independent experiments. Scale bars, 20 mM. (B)
Number of myotubes or MHC-positive cells per visual field. Ten randomly selected visual fields were photographed and the number of MHC positive
cells was plotted as indicated in the figure. P,0.05 (*), p,0.01 (
**) and p,0,001 (***). (C) Fusion indices for inhibitor (Go ¨6076 and Go ¨6983) treated
cultures in comparison to solvent controls are shown. Concentrations are indicated in the figure. Fusion indices were calculated as the number of
nuclei per myotube and sub-classified as 1 nucleus per myotube (upper left panel), 2-3 nuclei per myotube (upper right panel) or more than 3 nuclei
per myotube (lower panel). Ten randomly selected visual fields were evaluated. P,0.05 (*), p,0.01 (
**) and p,0.001 (***). (D) Immunoblot analysis for
MHC in differentiating C2C12 cells. Cultures were treated with inhibitors (Go ¨6076 and Go ¨6983) as indicated. One representative immunoblot out of
two is shown.
doi:10.1371/journal.pone.0014599.g004
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PLoS ONE | www.plosone.org 6 January 2011 | Volume 6 | Issue 1 | e14599Figure 5. shRNA-mediated PKD2 depletion inhibits myogenesis in vitro. (A) C2C12 cells were infected with lentiviruses encoding for
different shRNAs targeting PKD2 according to material and methods. After infection cells were selected for one week with puromycin to generate
stable cell lines. One representative immunoblot for PKD2 in different cells generated with the indicated shRNA lentivirus is shown. (B) Representative
bright field view of control virus transduced C2C12 cells (left photograph, control) and shRNA #4 targeting PKD2 (right photograph, PKD2-4) are
shown. Scale bars, 20 mM. (C) Control cells (Control) and shRNA#4 against PKD2-transduced cells (PKD2-4) were differentiated and collected as
indicated in the figure. Subsequent immunoblot analysis revealed diminished MHC expression in knock down cells. One representative immunoblot
PKD2 Regulates Differentiation
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Figure 6A). Next, we differentiated empty vector- and PKD2-
transduced C2C12 cells in our standard myogenic differentiation
assay. Forced PKD2 expression accelerated myoblast fusion and
increased the number of elongated cells resembling myotubes per
visual field. This was already visible on day 2 and continued until
the end of the experiment (Figure 6B). To assess that in a more
rigorous way, we measured cell length in randomly selected cells
(Control, n=2421; PKD2-OE, n=2090; three independent
experiments) without further facilitation via MHC-staining. To
define cell length in vector and PKD2-OE cells in greater detail we
defined three groups that exhibited ,100, 100-200, .200 mM cell
length. Most of the control cells could be allocated to the group
that contained ,100 mM cells while there were less PKD2-OE
cells in that group (Figure 6C; 82% vs. 37%; n=1996 vs.
n=782). This is in contrast to the second group where PKD2-OE
cells were predominantly found (Figure 6C; 16% vs. 51%;
n=408 vs. n=1067). In the third group (.200 mM) only a few
control cells could be found while PKD2-OE cells were the
predominat cell type (Figure 6C; 0,6% vs. 11%; n=16 vs.
n=240). Next, we calculated the overall cell length of all three
groups and found significant longer cells in the PKD2-OE cells in
line with increased differentiation (Figure 6D). As a more
quantitative approach MyoD and mAch (nicotinic, cholinergic
receptor) expression, was determined during differentiation of
C2C12 cells via qPCR (Figure 6E and 6F). MyoD serves hereby
as an early initiation marker and mAch as a mature marker for
myotubes[35,36,37,38,39]. In line with our morphological obser-
vations we detected increased and accelerated MyoD (Figure 6E)
expression as well as more mAch (Figure 6F) in particular at later
time points in C2C12 cells over-expressing PKD2. Immunoblot
analysis revaled a slightly increased level of myosin heavy chain on
day 3 with a marked increase on day 5 (Figure 6G). These data
indicate that expression of PKD2 is sufficient to accelerate
myogenic differentiation.
PKD2 contributes to myogenic differentiation of primary
satellite cells
To corroborate the data obtained in C2C12 cells, we
subsequently investigated the role of PKDs in primary isolated
murine satellite cells. A unique combination of cell-surface
markers (CD45
2Sca-1
2Mac-1
2CXCR4
+b1-integrin
+) defines au-
tonomously myogenic cells within the myofiber-associated satellite
cell compartment of adult mouse skeletal muscle and allows their
direct isolation by fluorescence-activated cell sorting (FACS) [41].
First, we isolated this particular cell type according to its surface
marker profile by FACS-sorting (Figure 7A). Isolated cells
exhibited the typical morphology of primary satellite cells cultured
in vitro (Figure 7B) and robust expression of nuclear Pax7 protein
(Figure 7C), a selective marker of primitive myogenic cells. PKD2
expression in primary satellite cells was verified by immunostain-
ing (Figure 7D). After initiation of differentiation by FGF- and
serum withdrawal, the cells were subsequently incubated with
either Go ¨6976 or Go ¨6983. We observed similar morphological
changes as in C2C12 cells including disrupted myotube fusion
upon treatment with the inhibitor. This observation points to a
pivotal role of the PKC/PKD pathway in myogenesis (Figure 7E).
PKD2 induces activation of Mef2D
Previously we have shown that PKD2 can activate Mef2D in
gastric cancer cells via phosphorylation of class II HDACs [14].
Mef2D is a transcription activator that binds specifically to the
MEF2 element present in the regulatory regions of many muscle-
specific genes and controls cardiac morphogenesis and myogen-
esis. Therefore, we hypothesized that Mef2 transcriptional
regulators could be potential myogenic targets of PKD2 in muscle
precursor cells. Exogenous expression of wild-type PKD2 or active
PKD2 in C2C12 myoblasts resulted in a 4.5- and 7-fold induction
of Mef2 promotor activity in C2C12 cells, respectively
(Figure 8A). The already high level of Mef2 promotor activity
in cells expressing PKD2 wild type is likely to be due to the fact
that exogenous expression of wild-type PKD2 in C2C12 cells
results in considerable activation of the kinase (data not shown). In
contrast, there was no significant increase in Mef2 promoter
activity compared to the expression of the empty vector plasmid
when cells expressed catalytically inactive PKD2 or a Mef2D
reporter plasmid containing mutated ME2D binding sites.
PKD2 inhibits transcriptional activity of Pax3
Pax genes have been shown to promote self-renewal and
population expansion in undifferentiated myoblasts. In C2C12
cells it has been shown that Pax3 overexpression increases
proliferation capacity and delays myogenic differentiation
[42,43,44]. We have demonstrated that PKD2 activates the pro-
myogenic transcription factor Mef2D. Next we examined whether
PKD2 was able to inhibit Pax3 transcriptional activity as another
mechanism to promote myogenic differentiation. To address this
question we performed Pax3 reporter assays in C2C12 cells
expressing different PKD2 mutants and Pax3. Exogenous
expression of wild-type PKD2 or catalytically inactive PKD2
(PKD2-DA) did not decrease Pax3 reporter activity. However,
coexpression of constitutively active PKD2 mutants [14,15] in
C2C12 myoblasts resulted in a reduction of 30% and 70% of Pax3
transcriptional activity, respectively, compared to PKD2 wild-type
and to a catalytically inactive mutant (Figure 8B and 8C). Thus
PKD2 can regulate myogenic differentiation by affecting two
transcriptional mechanisms, activation of Mef2D and inhibition of
Pax3 transcriptional activity.
Discussion
Muscle differentiation is regulated by an orchestrated network
of transcription factors that basically constitute two families; the
MyoD group bHLH muscle regulatory factors (MRFs) and the
MEF2 group of MADS-box regulators. It is a tightly controlled
process and can be induced in vitro by serum deprivation,
activation of RTKs, such as the insulin- or the IGF-1 receptor,
or by ligands of heptahelical receptors, such as S1P. At the
signaling level, various signaling pathways, including PLCb1 and
is shown. (D) Quantification of PKD2 immunoblots from (C) in three independent experiments is shown. P,0.05 (*) and p,0.01 (
**). (E) Control virus
(Control) infected cells and PKD2 knock down cells (PKD2-4) were seeded on cover slips. On day 3 and 5, cover slips were stained for MHC (green) and
nuclei (blue). Photographs are representative for three independent experiments. Scale bars, 20 mM. (F) Number of myotubes or MHC-positive cells
per visual field. Ten randomly selected visual fields were photographed and number of MHC positive cells were plotted as indicated in the figure.
Control cells (Con). PKD2 knock down cells (PKD2-4). Wilcoxon statistical test was used. P,0.05 (*), p,0.01 (
**). (G) Fusion indices of both stable cell
lines are shown. Control cells (Con). PKD2 knock down cells (PKD2-4). JFusion indices were calculated as the number of nuclei per myotube and sub-
classified as 1 nucleus per myotube (upper left panel), 2-3 nuclei per myotube (upper right panel) or more than 3 nuclei per myotube (lower panel).
Ten randomly selected visual fields were evaluated. P,0.05 (*), p,0.01 (
**) and p,0.001 (***).
doi:10.1371/journal.pone.0014599.g005
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PLoS ONE | www.plosone.org 8 January 2011 | Volume 6 | Issue 1 | e14599Figure 6. Ectopic expression of PKD2 increased myogenic differentiation. (A) C2C12 cells were infected with retroviruses encoding for
either EGFP or PKD2 according to material and methods After infection cells were selected for one week with neomycin to generate stable and pure
cell lines and analyzed via immunoblot for expression of the viral PKD2-transgene. To avoid overexposure and interference with the neighbouring
band a short exposure time was chosen in purpose. (B) Representative bright field view of control virus transduced C2C12 cells (left photograph) and
PKD2 overexpressing C2C12 cells (right photograph) are shown. Scale bars, 20 mM. (C) The percentage of cells in the respective group was calculated
with the following total numbers of counted cells: control, n=2421; PKD2-OE, n=2090 (n=3). Cells were grouped according to their cell length
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C2C12 myoblast differentiation [45,46,47]. Recently it has been
demonstrated that PKCe is up-regulated and its activity increases
during muscle differentiation. Furthermore, PKCe and PLCc1
were shown to form a complex and were found to be crucial for
insulin-induced myogenic differentiation. In addition, both
proteins co-localized with the Golgi marker 58-K in C2C12 cells
[45]. PLC enzymatic activity results in the production of inositol
1,4,5-trisphosphate and diacylglycerol (DAG). DAG activates not
only DAG-sensitive PKC isoforms including PKCe, but also
directly PKDs including PKD2 [48,49]. In addition, PKDs are
prominent downstream targets of PKCs, in particular novel
PKCg and e. On the other hand, the highly expressed class II
HDACs in skeletal muscle were known to repress the expression of
MEF2-dependent genes by directly binding to MEF2. The loss of
HDAC-MEF2 binding followed by the export of HDACs from the
nucleus to the cytoplasm is mediated by the members of CaMK
family. However, later studies have shown that PKDs were the
crucial players in this process by serving the role of downstream
effector kinases of PKCs and by stimulating the nuclear export of
class II HDACs [50]. Considering the critical role of HDACs in
regulating myocyte differentiation and remodeling and PKCs in
the signal transduction pathways of muscle differentiation, PKDs
could play an important role in muscle differentiation. Our data
show that C2C12 myoblasts express all PKD isoforms with PKD2
being the predominant isoform expressed during the entire course
of differentiation: PKD2 was phosphorylated/activated during the
initiation of C2C12 myoblast differentiation. Selective inhibition
of PKCs or PKDs as well as depletion of PKD2 by specific shRNA
constructs resulted in a marked inhibition of the expression of
Figure 7. Pharmacological inhibition of PKD activity reduces myogenic differentiation of primary satellite cells. (A) Schematic
overview of the performed FACS-sorting regimen. Sca1, CD11b and CD45 positive cells were excluded as hematopoietic cells. Cells being negative for
this marker population were gated as shown in the left panel. Gated cell were further analyzed for positive staining of CXCR4 and b1-integrin. Double
positive cells were considered as satellite cells and FACS-sorted. (B) FACS-sorted cells after one day of culture in vitro. Scale bars, 100 mM. (C) Satellite
cells stain positive for nuclear Pax7 (green). Nuclei are visualized by DAPI and are stained in blue color. Scale bar, 12.5 mM. (D) Satellite cells express
PKD2. PKD2 staining is shown in green, nuclei in blue. Scale bars, 37.5 mm. Insert shows higher magnification of single cell marked by the dashed
square. Arrows point on perinuclear localization of PKD2. Scale bar, 12.5 mM. (E) Cells were seeded on laminin coated cover slips and treated with
either Go ¨6983 or Go ¨6976 (both 10 mM). Bright field images were done after 2 days of initiation of differentiation. PKD inhibition in primary satellite
cells showed similar morphology with disrupted myotube fusion as C2C12 cells Scale bar, 100 mM.
doi:10.1371/journal.pone.0014599.g007
(,100, 100–200, .200 mM). Numbers of cells per group were as follows: ,100: 82% vs. 37%; n=1996 vs. n=782. 100–200 mM: 16% vs. 51%; n=408
vs. n=1067. .200 mM: 0.6% vs. 11%; n=16 vs. n=240. (D) Calculated means of all measured cells belonging to either control or PKD2-OE cells are
shown. (E and F) qPCR analysis for MyoD (E) and mAch (F) expression in stable C2C12 cells during differentiation at indicated time points. (G) Control
cells and PKD2 transduced cells were differentiated and collected as indicated in the figure. Subsequent immunoblot analysis revealed increased
MHC expression in knock down cells. One representative immunoblot is shown.
doi:10.1371/journal.pone.0014599.g006
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PLoS ONE | www.plosone.org 10 January 2011 | Volume 6 | Issue 1 | e14599Figure 8. PKD2-induced myogenesis is mediated via Mef2D activation and Pax3 repression. (A) C2C12 cells were co-transfected with
Mef2D-luc or Mef2D-luc mutated, Renilla and either wild type (PKD2-WT), catalytically active mutant (PKD2-S
706/710E) or catalytically inactive (PKD2-
DA) PKD2 constructs, respectively. Medium change from growth to differentiation medium occurred after 36 hours. After incubation with
differentiation medium for 24 hours, cells were harvested and luciferase assays were performed according to the manufacturer’s instructions. Graphs
were generated out of three independent and tested for significance using the Student t-test. P,0.05 (*) and p,0.01 (
**) are indicated. (B) Cells were
co-transfected with pcDNA3-Pax3-Flag, (PRS-9)-TK-CAT and/or pEGFP-PKD2 mutants as indicated. 24 hours upon transfection cells were harvested
and CAT ELISA was performed according to the manufacturer’s instructions. Graphs were generated out of three independent experiments and
tested for significance using the Student t-test. P,0.001 (***).
doi:10.1371/journal.pone.0014599.g008
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Pax7 and MHC and myotube formation, respectively. This
statement was further supported by data wherein the differenti-
ation of primary satellite cells was inhibited by treatment of either
PKC or PKD inhibitor. Thus, PKD2 appears to be required for
differentiation of C2C12 myoblasts.
The obtained expressions with our two independent PKD2
knock down cells are from particular interest. In fact it is
noteworthy that the alteration in myogenic genes during
differentiation was dose-dependent in terms of PKD2 expression.
The knock down in cell line #PKD2-2 was less efficient than in
cell line #PKD2-4 while the loss of the myogenic markers was
greater in cell line #PKD2-4. However, our expression data
clearly show that the myogenic program was not entirely disrupted
since e.g. myogenin and nicotinic cholinergic receptor were still
up-regulated. However, this is not surprising. The myogenic
program is highly conserved and tightly regulated [6]. The four
key factors-MyoD, myogenin, Myf5 and MRF4 act at multiple
points in the skeletal muscle lineage to establish the skeletal muscle
phenotype [6] and thereby serve as the most crucial players during
skeletal muscle myogenesis. However, both knock out mice of
MyoD and Myf5 lack any myogenic phenotype [6,51]. Given the
fact that even MyoD and Myf5 are functionally redundant it is not
surprising that myoblast differentiation is not finally governed by
just one kinase.
On the other hand, we observed a differential expression pattern
for the other two PKD isoforms. While PKD1 was expressed at very
low levels during the entire course of differentiation, PKD3 was
significantly upregulated at the terminal stage of differentiation. In
accordance, knockdown of PKD1 and PKD3 did not display any
significant effect on differentiation as judged by the expression of
marker gene-MyoD with the exception being the effect of PKD3
knockdown on the expression of a late differentiation maker gene,
mAch. However, this is explained by the fact that PKD3 is up
regulated at the terminal stages of differentiation and therefore
could play a role at this stage.
PKDs are major regulators of vesicle fission at the trans-Golgi
network (TGN) in many cells [52] and are targeted to the Golgi by
class I ARF proteins [53] where they are activated by local DAG
and bc subunits [54]. In C2C12 cells, PKD2 could be activated
via two ways, indirectly via PKCe [55], which is also active during
myogenic differentiation [45] or directly via PLC-mediated
production of DAG. We identified S1P as a potential physiological
activator of PKD2 in C2C12 cell myogenic differentiation.
Nevertheless, it is noteworthy that PKD2 depletion strongly
alters myogenic differentiation as shown at the level of morphol-
ogy, gene expression and finally on protein level. Vice versa, we
found increased myogenic differentiation upon overexpression of
PKD2 in C2C12 myoblasts. PKD2 activates Mef2Ds. It has been
shown previously that MEF2 factors and the myogenic bHLH
factors such as MyoD each regulate the expression of a number of
contractile protein genes. Thereby interaction between Mef2
proteins and the myogenic bHLH proteins is important in
directing muscle gene expression [2,3,4,6,51,56,57]. Furthermore,
we show, for the first time, that PKD2 negatively regulates Pax3
transcriptional activity. Pax3 has been shown to prevent
differentiation and increase self-renewal of C2C12 myoblasts in
a variety of studies [42,43,44,58]. Thereby, we propose that PKD2
functions in a dual mode of myoblast differentiation (i) repression
of self-renewal and (ii) induction of differentiation. Taken together,
these data identify PKDs, in particular PKD2 as a novel regulator
of muscle differentiation downstream of PKCe and PLCc and the
S1P receptor and thereby, as a potential novel target for the
modulation of muscle regeneration in myoblasts.
Materials and Methods
Cell lines and reagents
C2C12 cells were obtained from the European Collection of
Cell Cultures (Salisbury, UK) and cultured in DMEM (Invitrogen,
Karlsruhe, Germany) supplemented with 20% FCS (PAA, Co ¨lbe,
Germany) and 1% Penicillin/Streptomycin (Invitrogen). Cells
were induced to differentiate at 80–90% confluence by transfer-
ring them into DMEM plus 2% horse serum (differentiation
medium, [DM]), 1% Penicillin/Streptomycin and 1% Glutamax
(Invitrogen). The inhibitors Go ¨6976, Go ¨6983 as well as the
phorbol ester PMA were purchased from Calbiochem, Bad Soden,
Germany. Treatment of the inhibitors started with the switch from
growth to differentiation medium. Medium was replaced every
other day.
Western blot analysis
Immunoblot analysis was performed according to standard
protocols. C2C12 cells were harvested and dissolved either in lysis
buffer A (100 mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol,
0.01% phenol red, 100 mM dithiothreitol, protease inhibitor
tablet, Roche) or lysis buffer B (50 mM Tris/HCl, pH 7.6, 2 mM
EGTA, 2 mM EDTA, 1% Triton x-100, 2 mM DTT, protease
and phosphatase inhibitor cocktail. Whole cell extracts (50 mgt o
100 mg) were subjected to gel electrophoresis (SDS-PAGE) and
transferred to PVDF membranes (Millipore Corporation, Bedford,
USA). Membranes were blocked using 5% dry milk or BSA (for
phospho-PKD antibody) in phosphate-buffered saline containing
0.1% Tween 20. For subsequent washes, 0.1% Tween 20 in
phosphate-buffered saline was used. Membranes were incubated
o/n with specific antibodies at 4uC under shaking conditions. To
detect phosphorylated PKD we used a pPKD Ser744/748
antibody (1:1000; Cell Signaling, Danvers, USA). Anti-PKD1
antibody (1:1000) was purchased from Santa Cruz Biotech. Inc.,
Santa Cruz, USA). Anti-PKD2 and 3 antibodies (1:1000) were
from Bethyl Laboratories Inc., Montgomery, USA). Myogenin
and MHC antibodies were purchased from the Developemental
Hybridoma Bank (1:1000; University of Iowa, Iowa City, USA).
MyoD antibody (1:500) was obtained from Santa Cruz Inc.
Chemiluminescence was detected using a Chemi Smart Chemi-
luminescence 5000 documentation system (PeqLab Biotechnologie
GmbH, Erlangen, Germany).
Densitometric analysis
Densitometric analysis was performed by using BioProfil BIO-
1D software, version 12.04 (Vilber Lourmat Deutschland GmbH,
Eberhardzell, Germany). Relative band intensity of each time
point was measured and set in relation to either PKD2 or actin
loading control as indicated in the figure legend.
Immunoprecipitation
Immunoprecipitations were performed as described previous-
ly[53]. Briefly, C2C12 cells were lysed in lysis buffer A. After
centrifugation at 14,000 rpm for 10 min, protein concentrations
were measured in the lysates. 2000 mg of extracts were incubated
with 2 mg of either control IgG antibody (Santa Cruz Inc) or
PKD2 antibody at 4uC and after 1 h, 80 ml of protein A sepharose
beads were added and incubated for 1 h. Immobilized proteins
were washed extensively, and resuspended in Laemmli buffer and
subjected to SDS–PAGE and western blotting, as described above.
Quantitative one-step real-time RT-PCR (qPCR)
One-step real-time qPCR was carried out with the LightCyclerH
System (Roche, Mannheim, Germany) using the QuantiTect
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done as previously described [59]. Briefly, to verify the specificity
of the PCR amplification products, LightCycler melting curve
analysis was performed. Relative transcript expression was
expressed as the ratio of target gene concentration to the
housekeeping gene hydroxymethylbilane synthase (Hmbs) concen-
tration. QuantiTect primer assays (Qiagen) were used in all
experiments.
Immunocytochemistry
Immunofluorescence analysis was carried out with cells
cultivated on coverslips. The cells were rinsed in PBS and fixed
for 10 min with PBS containing 4% paraformaldehyde at room
temperature. For MHC/F-actin/DAPI co-staining, cells were
incubated for 10 min in 50 mM NH4Cl and subsequently treated
for 10 min with 0.1% Triton X (Sigma-Aldrich, Steinheim,
Germany) followed by 30 min incubation in 0.1% Goat serum
plus 1% fish skin gelatin (Sigma-Aldrich) for blocking. Then,
preparations were incubated with the primary antibody against
MHC (1:200; mouse anti-MF20 IgG, Developmental Hybridoma
Bank) in a humidified chamber o/n at 4uC. After washing three
times in PBS, cells were incubated for one hour at 37uC with an
Alexa 488-labeled rabbit anti-mouse IgG antibody and Alexa 568-
conjugated phalloidin (1:50; Invitrogen). Afterwards, cells were
washed in PBS again and treated with DAPI 1:5000 for 5 min.
Samples were subsequently washed and embedded in Vectashield
mounting medium (Vector, USA) and analysed by fluorescence
microscopy. For Pax7 (1:50; Developmental Studies Hybridoma
Bank) staining of primary isolated satellite cells, cells were spotted
on a glass slide. After drying the cells at room temperature, cells
were fixed for 10 min with PBS containing 4% paraformaldehyde.
Mouse antigens were blocked using the MOM kit (Vector Labs)
and permeabilized using Triton-X. Pax7 antibody was incubated
overnight at 4uC. After washing the preparations three times in
PBS, cells were incubated for one hour at 37uC with an Alexa 488-
labeled rabbit anti-mouse IgG antibody. Imaging was performed
with a Keyence inverted fluorescence microscope with filters
detecting excitations at 360 (Hoechst), 490 (Alexa Fluor 488), and
560 (Alexa Fluor 568) and a 60x oil objective. Images were
processed using ImageJ (http://rsbweb.nih.gov/ij/).
Lentiviral shRNA delivery and generation of stable cell
lines
All short hairpin shRNAs used in this study were constructed
in pLKO.1-puro. shRNAs for PKD2 were purchased from
Sigma-Aldrich (MISSIONH shRNA). Each gene set contained
four constructs with distinct target sequences, all of which were
packaged for viral production and infection, and tested for target
knockdown. For viral packaging, pLKO-shRNA, pCMV-dR8.91
and pCMV-VSV-G were co-transfected into 293T cells using
Fugene 6 (Roche) at 3 mg, 2,7 mg and 0,3 mg respectively (in 7 ml
for a 10 cm dish). Two rounds of transduction were carried out
with supernatant collected either after 24 or 48 hours in the
presence of 8 mg/ml polybrene (Sigma-Aldrich). Subsequently,
the cells were selected for 5 days in growth medium containing
3 mg/ml puromycin [9]. For depletion of PKD1 and 3, hairpins
were cut from the pSM2 Retroviral shRNAmir libraries (Open
Biosystems, Huntsville, USA) and cloned into the pGipz vector
(Open Biosystems). Three hairpins targeting either PKD1 or
PKD3 were then pooled and lentiviral particles were generated as
described above. Infected cells were purified with puromycin
(3 mg/ml). A pGipz vector harboring a scrambled shRNA served
as a control.
Retrovial infection and generation of stable cell lines
For retroviral packing pCL-Eco plasmid was co-transfected
together with PKD2-MSCVneo plasmid in 293T cells. Two
rounds of transduction were carried out with supernatant collected
either after 24 or 48 hours in the presence of 8 mg/ml polybrene
(Sigma-Aldrich). Subsequently, the cells were selected for 5 days in
growth medium containing 800 mg/ml neomycin.
Transient transfections and reporter assays
C2C12 cells were transfected with Lipofectamine (Invitrogen)
according to the manufacturer’s instructions. Luciferase activity
was determined using the Dual Luciferase Assay Kit (Promega,
Mannheim, Germany). Firefly luciferase relative light units were
normalized with renilla luciferase activity after co-transfection of a
pRL-TK plasmid (Promega). MEF2D reporter assays were
performed by co-transfecting 100 ng MEF2D and 2 mg of the
following vectors: PKD2-wild type, PKD2-S
706/710E double
mutant and catalytically inactive PKD2 mutant (PKD2-DA)
[60]. The expression level of reporter-only transfected C2C12
cells was used as reference luciferase activity and set to 1.
Myotube quantifications
Cells were stained for Myosin heavy chain (MHC) and DAPI
and 10 randomized visual fields per condition were photographed
in three independent experiments. Each MHC positive cell per
visual field was counted and defined as myotube. Fusion index was
built by counting manually nuclei of the MHC positive cells and
dividing them into three different groups: Myotubes containing
but one nucleus, two to three nuclei and more than three nuclei.
Measurement of cell length
To determine cell length in differentiating PKD2-OE versus
control C2C12 cells, 30 randomly selected high magnification
images were taken from three independent experiments. The
percentage of cells in the respective group was calculated with the
following total numbers of counted cells: control, n=2421; PKD2-
OE, n=2090 (n=3). Cells were grouped according to their cell
length (,100, 100-200, .200 mM).
Cat ELISA
To examine the effect of PKD2 on Pax3 transcriptional activity
C2C12 cells were transfected with the Lipofectamine LTX
(Invitrogen) according to the manufacturer’s specifications. The
LTX precipitate consisted of a combination of 1 mg of pcDNA3-
Pax3-Flag, 2 mg of the (PRS-9)-TK-CAT reporter plasmid,
containing the Pax3 paired and homeodomain recognition
sequences, and 5 mg of pEGP-PKD2 mutants. Analysis of
chloramphenicol acetyl transferase (CAT) level was performed
using the CAT ELISA Kit (Roche) according to the manufactur-
er’s specifications. All samples were corrected for the transfection
efficiency with respect to protein concentration. For protein
determination, Lowry and Bradford assays were used.
Satellite cell isolation
Satellite cells were prepared from hindlimb muscles (tibialis
anterior muscle, tibialis gastrocnemius muscle, soleus muscle) of 2–
3 month old mice. Briefly, muscles were digested in DMEM
(Invitrogen)/0.2% Collagenase Type II (Invitrogen) for 90
minutes, the muscle tissue was then mechanically dissociated with
a Pasteur pipette. After several steps of sedimentation and
washing, the myofibers were again enzymatically treated with
0.0125% Collagenase and 0.05% Dispase (Invitrogen) for 30
minutes to release satellite cells. Subsequently, satellite cells were
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markers: CD11b
- PE, CD45
- PE (1:200; eBioscience, San Diego,
USA), Sca-1
- APC (1:800; eBioscience), CXCR4
+ bio (1:100; BD
Pharmingen, Heidelberg, Germany) and b1-integrin
+ (1:200; BD
Pharmingen) purified, Streptavidin-PE-Cy7 (1:100; eBioscience),
anti-mouse IgG-FITC (1:100; eBioscience) [41]. Living cells were
labelled by positive staining for calcein blue (1:1000, Invitrogen)
and negative staining for propidium iodide (PI, 1 mg/mL). FACS
sorting was performed at a FACS Aria II cell sorter (Becton
Dickinson).
Satellite cell culture and differentiation
Prior to plating (24 hr), plates were coated with 0.2% rat-tail
collagen and 5 mg/mL natural mouse laminin (Invitrogen). Cells
were plated at 1610
4 cells/cm
2 in growth medium in either 24-
well tissue culture plates. Growth medium was composed of Ham’s
F10+20% FBS +5 ng/mL bFGF (Invitrogen) +1% penicillin/
streptomycin +1% Gluta-Max. bFGF was replaced daily. After 5–
7 days, cells were passaged by aspiration of medium, washing with
PBS, and incubation with PBS for 5 min at 37uC. Cells then were
replated onto collagen/laminin-coated chamber slides in growth
medium for 2 days, and then medium was changed to
differentiation medium: Opti-MEM (Invitrogen) +1% FBS +1%
penicillin/streptomycin +1% GlutaMax. Inhibitor treatment
(Go ¨6983, Go ¨6976) was done as described for C2C12 cells.
Ethical Treatment of Animals
The animal work on primary mouse satellite cells was approved
by the government of the state of Baden-Wu ¨rttemberg (Regier-
ungspra ¨sidium Tu ¨bingen 35/9185.81-3; Permit number No.919).
All efforts were made to minimize suffering of the animals. No
experiments were performed on living animals.
Statistical analysis
For all figures in this study, if not stated otherwise, standard
errors of the mean (s.e.m.) are indicated by error bars, and p-values
by student t-test ,0.05, 0.01 or 0.001 are indicated by either one,
two or three asterisks, respectively. In case of using Wilcoxon
statistical test, p-values ,0.05 or 0.01 are indicated in the figure
legend, respectively.
Supporting Information
Figure S1 C2C12 cell differentiation recapitulates myogenesis in
vitro. Wild type C2C12 cells were seeded on day -1 to achieve a
confluency of approximately 70% at day 0. Differentiation of
C2C12 cells was induced by change of medium from growth
medium to differentiation medium. At day 1 of differentiation,
cells become more confluent and start developing alignment. On
day 3 of differentiation, first small myotubes are detectable. At day
6 of differentiation, myotubes become more elongated, multinu-
cleated and ramified. Scale bar, 100 mM. Shown is one
representative serie of bright field photographs out of 6
independent identical experiments.
Found at: doi:10.1371/journal.pone.0014599.s001 (11.56 MB
TIF)
Figure S2 Specificity of PKD2 antibody detecting only PKD2
but not PKD1 or PKD3. Hek-293T cells were transfected with
expression vectors harboring GFPfusion proteins with each PKD
isoform. The respective lysates were subsequently analyzed via
immunoblotting with PKD2 antibody. Upper band shows
exclusive detection of the EGFP-PKD2 fusion protein in cells
transfected with the respective plasmid. No signals were detected
in PKD1-GFP and PKD3-GFP transfected variants. All groups
showed endogenous PKD2 expression as shown by the weak band
(low intensity band). (*) marks unspecific bands.
Found at: doi:10.1371/journal.pone.0014599.s002 (1.38 MB TIF)
Figure S3 Pharmacological inhibition of PKCs and PKDs
inhibits myoblast differentiationi nv i t r o .( A )C e l l sw e r es e e d e d
on cover slips and treated with either Go ¨6976 or Go ¨6983.
Concentrations are indicated in the figure. DMSO served as a
solvent control and did not affect myogenic differentiation of
C2C12 cells. On day 5, cover slips were stained for MHC
(green), f-actin (red) and nuclei (blue). Photographs are
representative for 3 independent experiments. Scale bars,
20 mM. (B) Number of myotubes or MHC positive cells per
visual field. Ten randomly selected visual fields were photo-
graphed and number of MHC positive cells were plotted as
indicated in the figure. P,0.05 (*), p,0.01 (**), and p,0.001
(***). (C) Fusion indices for inhibitor (Go ¨6076 and Go ¨6983)-
treated cultures in comparison to solvent controls are shown.
Concentrations are indicated in the figure. Fusion indices were
calculated as the number of nuclei per myotube and sub-
classified as 1 nucleus per myotube (upper left panel), 2-3 nuclei
per myotube (upper right panel) or more than 3 nuclei per
myotube (lower panel). Ten randomly selected visual fields were
evaluated. P,0.05 (*), p,0.01 (**), and p,0.001 (***).
Found at: doi:10.1371/journal.pone.0014599.s003 (5.97 MB TIF)
Figure S4 PKC and PKD inhibitors alter myotube morphology
differently. (A-B) Length and width of myotubes per visual fields
were measured using Image J. Length-to-width ratio was
calculated and mean values were plotted as indicated in the figure
for either day 3 (A) or day 5 (B). Ten randomly selected visual
fields were evaluated. P,0.05 (*), p,0.01 (**) and p,0.001 (***).
Found at: doi:10.1371/journal.pone.0014599.s004 (0.65 MB TIF)
Figure S5 PKD2-depleted cells show altered expression of
myogenic markers. Scramble-, shRNA-PKD2 construct #2 and
shRNA-PKD2 construct #4 infected cells were differentiated for 5
days and mRNA samples were collected. qPCR for Pax7 (A),
MyoD (B), Myogenin (C), Mef2D (D) and mAch [nicotinic,
cholinergic receptor, (E)] expression (n=3).
Found at: doi:10.1371/journal.pone.0014599.s005 (1.34 MB TIF)
Figure S6 PKD2-depleted cells show normal proliferative
capacity. (A) The CellTiter-Glo Luminescent Cell Viability Assay
was used to determine the number of viable cells in cultures based
on quantitfication of the ATP present. Values represent measure-
ment of relative light units (RLU) 48 hours after seeding equal
numbers of cells (n=3). (B) Quantification of percentage of cells
being in either G1-, S or G2/M-phase (n=3). (C and D)
Representative cell cycle plot for control vs. shRNA PKD2-2 (C)
and shRNA PKD2-4 (D). (E) Immunoblot analysis for Cyclin D1
in Control- and PKD2-depleted cells after 24 hours of culture in
growth medium. Representative immunoblot out of three
independent experiments.
Found at: doi:10.1371/journal.pone.0014599.s006 (1.89 MB TIF)
Figure S7 PKD1 and PKD3 are less critical for C2C12
myoblast differentiation. (A-B) Generation of stable C2C12 cell
lines after lentiviral infection with either scramble shRNA (Con) or
a pool of shRNAs targeting either PKD1 (A) or PKD3 (B). (C)
qPCR analysis of MyoD on day 3 and day 5 of differentiation of
the indicated cell lines. (D) qPCR analysis of mAch on day 3 and
day 5 of differentiation of the indicated cell lines. N=3; n.s.=not
significant.
Found at: doi:10.1371/journal.pone.0014599.s007 (1.66 MB TIF)
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